Chemical formula: C₂₈H₄₅NO₅S Molecular mass: 507.73 g/mol PubChem compound: 25185057
Lefamulin is a pleuromutilin antibacterial agent. It inhibits bacterial protein synthesis by interacting with the A- and P- sites of the peptidyl transferase centre (PTC) in the central part of domain V of the 23S rRNA of the 50S ribosomal subunit, preventing correct positioning of the tRNA. Lefamulin is indicated for the treatment of community-acquired pneumonia (CAP) in adults.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J01XX12 | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01X Other antibacterials → J01XX Other antibacterials | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| XENLETA Solution for injection / Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Lefamulin is an active ingredient of these brands:
United States (US)
Austria (AT)
Croatia (HR)
Estonia (EE)
Ireland (IE)
Italy (IT)
Lithuania (LT)
Poland (PL)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
